Scienture Holdings Inc (SCNX) FinancialsSCNXScienture Holdings Inc

Scienture Holdings Inc (SCNX) generates its revenue primarily from Integra pharma, LLC, which accounts for 100.0% of total sales, equivalent to $10.26K. Understanding this concentration is critical for investors evaluating how SCNX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Scienture Holdings Inc maintains a gross margin of 97.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -785.63%, while the net margin is -821.32%. These profitability ratios, combined with a Return on Equity (ROE) of -53.47%, provide a clear picture of how effectively SCNX converts its operational activities into shareholder value.

In the context of the broader market, SCNX competes directly with industry leaders such as GRML and FOFO. With a market capitalization of $16.18M, it holds a significant position in the sector. When comparing efficiency, SCNX's gross margin of 97.71% stands against GRML's N/A and FOFO's 100.00%. Such benchmarking helps identify whether Scienture Holdings Inc is trading at a premium or discount relative to its financial performance.

The company has shown a significant revenue increase in Q1 2026 with $56,325, but still faces substantial net income losses, with -$2,822,371 reported for Q2 2026. The gross margin is high at 97.71% for Q2 2026, indicating potential profitability if revenue stabilizes.